Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial

Published:2023-05 Issue:5 Volume:10 Page:e322-e332
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Srivastava Alok,Rangarajan Savita,Kavakli Kaan,Klamroth Robert,Kenet Gili,Khoo Liane,You Chur-Woo,Xu Weiqun,Malan Niel,Frenzel Laurent,Bagot Catherine N,Stasyshyn Oleksandra,Chang Chia-Yau,Poloskey Stacey,Qiu Zhiying,Andersson Shauna,Mei Baisong,Pipe Steven W

Funder

Sanofi Genzyme

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. The central role of thrombin in bleeding disorders;Negrier;Blood Rev,2019

2. WFH Guidelines for the Management of Hemophilia, 3rd edition;Srivastava;Haemophilia,2020

3. Future of coagulation factor replacement therapy;Peyvandi;J Thromb Haemost,2013

4. Current challenges in the management of hemophilia;Bauer;Am J Manag Care,2015

5. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study;Male;Haematologica,2021

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. RNA therapeutics to control fibrinolysis: review on applications in biology and medicine;Journal of Thrombosis and Haemostasis;2024-08

3. Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?;Expert Opinion on Pharmacotherapy;2024-07-23

4. Fitusiran reduces bleeding in factor X–deficient mice;Blood;2024-07-11

5. Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders;ACTA PHARM SIN B;2024